# Glutamate Inhibitors in Glioblastoma

> **NCT05664464** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Zurich** · enrollment: 120 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Gabapentin
- **DRUG:** Sulfasalazine
- **DRUG:** Memantine
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05664464
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05664464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05664464, "Glutamate Inhibitors in Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05664464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*